Hepatic Fibrosis Biomarkers

Global Hepatic Fibrosis Biomarkers Market Size is projected to reach USD 3090.5 Million by 2035

According to a research report published by Spherical Insights & Consulting, the Global Hepatic Fibrosis Biomarkers Market is expected to grow from USD 419.5 million in 2024 to USD 3090.5 million by 2035, at a CAGR of 19.91% during the forecast period 2025-2035.

Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the Global Hepatic Fibrosis Biomarkers Market Size, Share, and COVID-19 Impact Analysis, By Product (Kits And Reagents, Assays, and Services), By Technology (Immunoassay, Molecular Diagnostics, Proteomics/Metabolomics, and Imaging-Based Biomarker Assessment), By End Use (Hospitals, Diagnostic Laboratories, Specialty Clinics, Academic & Research Institutes, and Pharmaceutical & Biotechnology Companies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035. https://www.sphericalinsights.com/reports/hepatic-fibrosis-biomarkers-market     

The hepatic fibrosis biomarkers market refers to the worldwide industry involving the development and sale of non-invasive blood tests and imaging techniques for diagnosing and staging liver fibrosis. Hepatic fibrosis biomarkers are blood-based, non-invasive indicators (direct or indirect) used to assess the accumulation of scar tissue in the liver, serving as an alternative to liver biopsy. Fibrosis prediction is important for chronic liver disease, in which blood-based biomarkers provide a number of advantages include safety, cost-savings, and wide accessibility over other traditional standards of fibrosis assessment of liver biopsy. Innovation and market expansion are anticipated as a result of major players' increasing R&D on investigating the utility of combining several biomarkers for enhancing diagnostic accuracy. An increasing prevalence of NASH (nonalcoholic steatohepatitis), obesity, sedentary lifestyles, and metabolic syndrome is driving the hepatic fibrosis biomarkers market. On the contrary, increased cost of advanced diagnostic tests, limited reimbursement policies, and lack of standardization across various biomarker panels are challenging the hepatic fibrosis biomarkers market.

The kits and reagents segment dominated the market, accounting for about 47.0% in 2024, and is projected to grow at a substantial CAGR over the forecast period.

Based on the product, the hepatic fibrosis biomarkers market is divided into kits and reagents, assays, and services. Among these, the kits and reagents segment dominated the market, accounting for about 47.0% in 2024, and is projected to grow at a substantial CAGR over the forecast period. Kits like BioPredictive’s Fibro Test and GENFIT’s NIS4 panel set benchmarks for non-invasive liver fibrosis detection, providing reproducibility and compatibility with high-throughput analyzers.   

The immunoassay segment accounted for the largest market share of around 43.9% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.

Based on the technology, the hepatic fibrosis biomarkers market is divided into immunoassay, molecular diagnostics, proteomics/metabolomics, and imaging-based biomarker assessment. Among these, the immunoassay segment accounted for the largest market share of around 43.9% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Immunoassay technology enables the identification of fibrosis stages and monitoring of treatment response, especially for HBV, HCV, metabolic dysfunction-associated fatty liver disease.

The hospitals segment dominated the market with the largest share of nearly 38.0% in 2024 and is anticipated to grow at a substantial CAGR during the forecast period.

Based on the end use, the hepatic fibrosis biomarkers market is divided into hospitals, diagnostic laboratories, specialty clinics, academic & research institutes, and pharmaceutical & biotechnology companies. Among these, the hospitals segment dominated the market with the largest share of nearly 38.0% in 2024 and is anticipated to grow at a substantial CAGR during the forecast period. High patient volume, the availability of advanced diagnostic infrastructure, and the integration of biomarker testing into standard hepatology and gastroenterology care pathways are contributing to the market growth.  

North America is expected to hold the majority share of the global Hepatic Fibrosis Biomarkers market during the forecast period.

North America is expected to hold the majority share of around 48.1% in the global hepatic fibrosis biomarkers market during the forecast period. The U.S. is dominating the North America market with the largest share, owing to the upsurging demand for non-invasive alternatives to liver biopsy. North America has a robust market ecosystem driven by the region's increased prevalence of chronic liver diseases (NAFLD, NASH, Hepatitis), demand for non-invasive diagnostic tools over liver biopsies, and advanced healthcare infrastructure. Key industry players, including GENFIT, Siemens Healthineers, Quest Diagnostics, Labcorp, and Echosens (Fibroscan), providing serum tests and imaging-based diagnostics for non-alcoholic steatohepatitis (NASH) and liver fibrosis, also play an important role in the market.

Asia Pacific is anticipated to grow at the fastest pace of approximately 21.5% in the global hepatic fibrosis biomarkers market during the forecast period. China is the leading country in Asia Pacific hepatic fibrosis iomarkers in terms of share, due to its large patient population and strong adoption of diagnostic technologies. In the Asia Pacific hepatic fibrosis biomarkers market, there is a growing prevalence of liver diseases such as hepatitis B/C, and a surge in NAFLD/NASH, which is driven by lifestyle changes, obesity, and diabetes. Further, the ongoing study on liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease is anticipated to propel market growth.  

Major vendors in the global hepatic fibrosis biomarkers market are GENFIT, Prometheus Laboratories, Siemens Healthineers AG, BioPredictive, Quest Diagnostics, AstraZeneca, Exalenz Bioscience Ltd (Meridian Bioscience), Labcorp, Pfizer Inc., Bristol-Myers Squibb Company, and Others.  

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Key Market Development 

• In March 2025, Precision BioSciences, Inc., a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PBGENE-HBV.

• In November 2024, Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company leveraging its extensive virology expertise, and Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates, announced new preliminary data from the Phase 2a IM-PROVE II clinical trial (AB-729-202) of people with chronic hepatitis B virus (cHBV) at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting 2024.  

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Hepatic Fibrosis Biomarkers market based on the below-mentioned segments:

Global Hepatic Fibrosis Biomarkers Market, By Product

• Kits and Reagents
• Assays
• Services

Global Hepatic Fibrosis Biomarkers Market, By Technology

• Immunoassay
• Molecular Diagnostics
• Proteomics/Metabolomics
• Imaging-Based Biomarker Assessment

Global Hepatic Fibrosis Biomarkers Market, By End Use

• Hospitals
• Diagnostic Laboratories
• Specialty Clinics
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies

 Global Hepatic Fibrosis Biomarkers Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

 
CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter